• 3 October 2017

    Can J&J’s sirukumab survive FDA rejection?

    On September 22, Johnson & Johnson (J&J) received a complete response letter from the FDA for sirukumab for the treatment of moderate to severe rheumatoid arthritis (RA).

  • 26 July 2017

    NICE: too nice for too long?

    The UK’s National Institute for Health and Care Excellence (NICE) advises the NHS on what drugs, devices, and technologies to buy in England and Wales using evidence-based data on incremental...